Muscle Invasive Urothelial Carcinoma
Advertisement
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
Dr. Faltas highlights CLONEVO, a trial using preoperative abemaciclib in cisplatin-ineligible MIBC with ctDNA monitoring.
Drs. Galsky and Tawagi discuss the NIAGARA trial on perioperative durvalumab in combination with chemotherapy for MIBC.
Interim SURE-02 study examines sacituzumab govitecan plus pembrolizumab in patients with MIBC unfit for chemotherapy.
ctDNA analysis from the NIAGARA trial offers new insights for patients with MIBC receiving perioperative durvalumab.
Dr. Zlotta discusses the current state and future of bladder-sparing therapy in MIBC, including how to best select patients.
Researchers find promise for ctDNA-guided immunotherapy for patients with MIBC who underwent radical cystectomy.
[68Ga]-FAPI-PET/MRI and [18F]-FDG-PET/CT share similar diagnostic accuracy for tumor staging in patients with MIBC.
At the time of a pre-specified interim analysis, significant improvements in EFS and OS were seen.
Dr. Plimack details RETAIN, from early findings with neoadjuvant ddMVAC to the evolution of RETAIN-1 and RETAIN-2.
Preliminary results of the study showed promising efficacy and safety with neoadjuvant treatment with DV plus toripalimab.
Drs. Ghatalia and Nizam break down in detail the RETAIN-2 study, a phase 2 trial of risk enabled therapy for MIBC.
Dr. Galsky highlights the latest findings on the impact of pCR on long-term outcomes in the NIAGARA trial.
Dr. Galsky provides comment on the additional efficacy outcomes in patients with MIBC from the CheckMate 274 study.
The interim analysis of the RETAIN-2 trial demonstrated a 46% pT0 rate among those undergoing cystectomy.
Nivolumab demonstrated sustained DFS benefits across all patients with MIBC and in prior NAC subgroups.
Dr. Geynisman shares insights on the feasibility of bladder-sparing approaches in treating muscle-invasive bladder cancer.
Using mpMRI before TURBT may be beneficial for patients with suspected MIBC.
Dr. Geynisman reviews the RETAIN 1 trial evaluating whether certain patients with MIBC can safely avoid invasive procedures.
Durvalumab was granted FDA Priority Review for MIBC, after showing significant survival benefits in the NIAGARA trial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.